MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.